Decoy Therapeutics Inc. (DCOY) intrinsic value & 10-year financials
Decoy Therapeutics Inc. (DCOY) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.17
- Market cap
- $113.5K
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 12.7%
- ROIC (10-yr avg)
- -122.2%
- Free cash flow (FY2025)
- -$5.4M
DCOY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$12.5M | -$129.10 | -$5.4M | — | -340.9% |
| FY2024 | — | -$5.6M | -$5.79 | -$4.5M | — | -164.0% |
| FY2023 | — | -$12.5M | -$3.84 | — | — | -160.1% |
| FY2022 | $0 | -$31.6M | -$14.88 | — | — | -128.7% |
| FY2021 | $1.8M | -$12.8M | -$0.31 | -$10.2M | -696.3% | -41.9% |
| FY2020 | $5.2M | -$7.4M | -$0.50 | -$10.3M | -148.8% | -44.9% |
| FY2019 | $3.5M | -$6.9M | — | -$11.6M | -238.5% | -83.2% |
| FY2018 | $838.1K | -$21.9M | — | -$23.6M | -2633.7% | -114.2% |
| FY2017 | $1.3M | -$34.4M | — | -$27.8M | -2724.6% | -77.9% |
| FY2016 | $1.0M | -$39.5M | — | -$32.6M | -3946.5% | -66.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Decoy Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Decoy Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -56.4% ROIC.
Decoy Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Decoy Therapeutics Inc. is modeled at 12.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3782.48 per share.